N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer
Yan-Rong Wen, Xia-Wen Lin, Yu-Wen Zhou, Lei Xu, Jun-Li Zhang, Cui-Ying Chen, Jian He
Yan-Rong Wen, Xia-Wen Lin, Jian He, Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China
Yu-Wen Zhou, Lei Xu, Jun-Li Zhang, Cui-Ying Chen, Department of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing 210008, Jiangsu Province, China
Co-first authors: Yan-Rong Wen and Xia-Wen Lin.
Co-corresponding authors: Cui-Ying Chen and Jian He.
Author contributions: All authors contributed to the study conception and design. Wen YR and Lin XW contributed equally to this work; Lin XW and He J collected the samples and conducted the data analysis; Zhou YW, Xu L, Zhang JL, and Chen CY performed N-glycans analysis; Wen YR and He J designed the research, analyzed data and wrote the manuscript. He J and Chen CY are the co-corresponding authors of this study. He J and Chen CY were involved in the experimental design and revision of the article. Specifically, He J assumed responsibility for the overall design of the subject, Chen CY focused on the experimental design of the N-glycan analysis.
Supported by fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University, No. 2021-LCYJ-MS-11.
Institutional review board statement: The study protocol was approved by the Ethics Committee of Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School and conformed to the ethical guidelines of the Declaration of Helsinki.
Informed consent statement: Written informed consent was obtained from all patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at hjxueren@126.com.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Jian He, Doctor, PhD, Chief Doctor, Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China. hjxueren@126.com
Received: October 5, 2023
Peer-review started: October 5, 2023
First decision: December 6, 2023
Revised: December 21, 2023
Accepted: January 18, 2024
Article in press: January 18, 2024
Published online: March 15, 2024
